Review: Current Efforts in 3D Printed Pharmaceuticals and Drug-Delivery Systems

IMTS

Share this Article

International researchers continue to explore the potential of patient-specific treatment via 3D printing, releasing their findings regarding pharmaceuticals in the recently published ‘3D Printing of Pharmaceuticals and Drug Delivery Devices.’

Although greater affordability and accessibility of 3D printers means that the technology is impacting numerous major industries, the strides being made in the medical field are impressive, including medical devices like implants and prosthetics, tissue engineering and a wide variety of different innovations regarding medication and drug delivery. In this review, the researchers discuss current progress in bioprinting, 3D printing applications for drug delivery, and the potential for 3D printing technology as related to pharmaceuticals and medicine in the future.

Extrusion-based Fused Deposition Modeling (FDM) is one of the most used methods of 3D printing due to affordability, good print quality, and the capability for loading drugs into filaments. Implants can be fabricated with a variety of different materials, some of which are biodegradable—and some of which are not. Research teams such as Stewart et al. have also modified implants to include coatings, thus extending release profiles. Others like Giri et al. have created gastro-retentive floating tablets (GRFT), again featuring drug-loaded filaments.

Similiar research, such as studies performed by Azad et al. have centered around the importance of singling out suitable polymers for extrusion-based 3D printing, assessing mechanical properties and success of experimental mixtures.

From Azad et al., Characterizations required for 3D printed structure, drug, and polymer (or other functional excipients, if necessary). From ‘Polymers for Extrusion‐Based 3D Printing of Pharmaceuticals: A Holistic Materials–Process Perspective

“They confronted 3DP with the current process of direct compression and evidenced the importance to know the rheological properties of the polymers and polymer–API mixture in order to predict their impact on the printing process and on the final dosage form,” explain the authors. “They also discussed which kind of characterization methods are required for 3D printed structure, drug, polymer and other functional excipients. Finally, examined the challenges and opportunities related to pharmaceutical extrusion-based 3DP.”

Kjar and Huang also investigated various applications related to micro-manufacturing, along with drug delivery. Araújo et al. offered a study based around the concept of pharmacies turned digital, with on-demand fabrication of patient-specific dosages.

“Pharmaceutical companies will need to work in unison with these digital pharmacies for the large-scale production of extruded filaments, which the digital pharmacies can later use to print. The regulatory concerns surrounding 3DP were also evaluated showing that patents have hindered 3DP products from reaching the market and there should be greater cooperation between regulatory and patenting authorities to ensure that 3DP products can reach the market,” said the authors.

Other researchers such as Domínguez-Robles et al. experimented with creating PLA filaments accentuated with natural materials like lignin, while yet others such as Alhijjaj et al. focused on the critical need for improved process parameters in 3D printing of pharmaceuticals, discussing both macroscopic and microstructural reproducibility.

Other typical 3D printing techniques associated with pharmaceuticals include:

  • Stereolithography (SLA) – proven effective for fabrication of solid dosage forms, promoting patient-specific medication, and drug-release systems.
  • Selective Laser Sintering (SLS) – previous research teams like Awad et al. have successfully manufactured miniprintlets for small dosages, creating samples with paracetamol and ibuprofen.
  • Bioprinting – bioprinted scaffolding structures have proven successful in applications like bone regeneration and healing of fractures, as well as bio-inks being created for wound dressings—both direct and indirect.

More alternative forms include digital light processing (DLP), stencil printing, embedded printing (e-3DP), and semi-solid extrusion printing (EXT).

HP’s new bioprinter helps researchers fabricate pharmaceutical samples (Image: HP)

“There is an increasing research using multiple types of 3DP. However, one of the main advantages common to all available types of 3DP is the ability to create personalized medicine. AM, due to its ease of use, speed and accessibility is increasingly promoting the creation of medical devices and pharmaceutical products on demand for patients within a clinical setting,” concluded the authors. “The ability to change the release profile and dosing of a 3D printed tablet simply by changing the geometries using CAD and the ability to incorporate drugs into FDM printed injectable devices or mesh implants using HME, opens up a wide range of possibilities within the application of 3DP in the medical field.

“However, more research does need to be conducted in the field before the production of 3D-printed products on demand can become a reality within a clinical setting, such as the effect of process parameters on the print quality and how reproducibility in 3DP can be improved. FDM is also limited to the number of drugs that can be loaded into filaments, as they need to withstand the high temperatures of the process. However, if research continues to rise in the area of 3DP, due to the versatility of 3D printed products and the number of manufacturing advantages that 3DP offers there is potential for more 3DP to leave the proof of concept stage and be developed into a widely used manufacturing tool.”

What do you think of this news? Let us know your thoughts; join the discussion of this and other 3D printing topics at 3DPrintBoard.com.

[Source: ‘3D Printing of Pharmaceuticals and Drug Delivery Devices’]

Share this Article


Recent News

Will There Be a Desktop Manufacturing Revolution outside of 3D Printing?

Know Your Würth: CEO AJ Strandquist on How Würth Additive Can Change 3D Printing



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

Featured

Pressing Refresh: What CEO Brad Kreger and Velo3D Have Learned About Running a 3D Printing Company

To whatever extent a business is successful thanks to specialization, businesses will nonetheless always be holistic entities. A company isn’t a bunch of compartments that all happen to share the...

Würth Additive Launches Digital Inventory Services Platform Driven by 3D Printing

Last week, at the Additive Manufacturing Users’ Group (AMUG) Conference in Chicago (March 10-14), Würth Additive Group (WAG) launched its new inventory management platform, Digital Inventory Services (DIS). WAG is...

Featured

Hypersonic Heats Up: CEO Joe Laurienti on the Success of Ursa Major’s 3D Printed Engine

“It’s only been about 24 hours now, so I’m still digesting it,” Joe Laurienti said. But even via Zoom, it was easy to notice that the CEO was satisfied. The...

Featured

3D Printing’s Next Generation of Leadership: A Conversation with Additive Minds’ Dr. Gregory Hayes

It’s easy to forget sometimes that social media isn’t reality. So, at the end of 2023, when a burst of doom and gloom started to spread across the Western world’s...